Candida Vaccines Forecast
Including Candida auris
Candida disease spans two very different worlds. Recurrent vulvovaginal candidiasis (RVVC) is a common, quality-of-life-limiting condition affecting an estimated 138 million women worldwide, while invasive candidiasis is a life-threatening bloodstream infection concentrated in hospital ICUs. Since this report's 2020 edition, a third and distinct concern has emerged: Candida auris, a multidrug-resistant, healthcare-associated pathogen now rated a WHO critical-priority fungal threat in its own right. This report models the commercial opportunity for vaccines addressing all three, and is well overdue a refresh to reflect them.
- Format
- Executive presentation + Excel model
- Coverage
- Major Western markets
- Indications
- RVVC (LO/MID/HI) + invasive candidiasis (ICU)
- Forecast horizon
- To 2035
- Approach
- Value ($m)/volume (mio doses) by scenario
- Base edition
- 2020
- Availability
- Syndicated / bespoke
vulvovaginal candidiasis worldwide
candidiasis (candidemia) in ICU settings
across US states in 2025 alone
C. albicans and C. auris (2022 list)
One genus, three very different vaccine opportunities
Candida yeasts sit behind a remarkably wide spectrum of human disease, from a common and often recurrent mucosal infection through to a life-threatening bloodstream infection, and now a distinct, multidrug-resistant healthcare threat. This review sets out the full picture before turning to the R&D landscape now forming around it.
Pathogen overview - from vulvovaginal disease to Candida auris
Candida species are yeasts that live commensally in the human gut, mouth and vagina in most healthy people, but can turn opportunistic pathogens when local or systemic defences are disrupted. Candida albicans has historically dominated clinical isolates and remains the best-characterised species, but so-called non-albicans species, including Nakaseomyces glabrata (formerly Candida glabrata), Candida tropicalis, Candida parapsilosis and Pichia kudriavzevii (formerly Candida krusei), now account for a growing share of bloodstream infections and are typically less susceptible to first-line azole antifungals. This shifting species mix, and the resistance trends that come with it, is a central theme of the report's competitor and epidemiology sections.
At the mucosal end of the spectrum sits vulvovaginal candidiasis (VVC), commonly known as a yeast infection: nearly 75% of adult women experience at least one episode in their lifetime. A meaningful minority, estimated at 5-9% of women, go on to develop recurrent vulvovaginal candidiasis (RVVC), conventionally defined as three or more symptomatic episodes a year. Recent literature puts the global RVVC population at an estimated 138 million women worldwide, a burden that causes considerable inconvenience, distress and lost productivity, yet remains served largely by repeat courses of the same azole antifungals, with growing reports of azole resistance in recurrent cases. It is this unmet need, chronic, high-prevalence and currently unaddressed by any preventive vaccine, that anchors the RVVC side of this report's forecast.
At the opposite end sits invasive candidiasis, a life-threatening bloodstream infection (candidemia) that mainly affects patients with serious underlying co-morbidities, most often in the hospital intensive care unit. It remains one of the most common healthcare-associated bloodstream infections in ICU settings, broadly consistent with the CDC figures this report's original edition cited placing it among the leading causes of ICU bloodstream infection. Contemporary data shows attributable mortality of 30-50%, rising above 70% in the highest-risk cohorts, alongside long ICU stays and substantial healthcare costs, with US inpatient costs alone estimated at over five billion dollars a year. Non-albicans, fluconazole-resistant species have become more prominent in ICU candidemia since the COVID-19 pandemic, further complicating first-line treatment choices.
Candida auris is a distinct and more recently emerged threat that this report's original edition, predating essentially the modern era of this pathogen, could not have covered. First described in 2009 from an ear canal isolate in Japan, C. auris rose to global prominence from around 2016 onward as it was identified, seemingly independently, on multiple continents. Unlike most Candida species, it spreads readily from patient to patient within healthcare settings, persists on skin and hospital surfaces for extended periods, and resists many standard disinfectants, properties that have driven a series of hospital and long-term care facility outbreaks worldwide. Surveillance data shows the scale of that spread: cases reported to health authorities across dozens of US states approached record levels again in 2025, with over 7,000 clinical cases identified and the organism now reported in more than 60 countries. Antifungal resistance is the other defining feature: fluconazole resistance exceeds 90% in the dominant clades, and pan-resistant isolates, resistant to all three major classes of antifungal drug, have now been documented. In October 2022 the World Health Organization placed C. auris in the critical-priority group of its first-ever fungal priority pathogens list, alongside C. albicans, Aspergillus fumigatus and Cryptococcus neoformans, a rare instance of two species from the same genus both reaching the top tier.
An early-stage pipeline, and honest ground still to cover on Candida auris
This report's 2020 edition predates essentially the entire modern Candida vaccine pipeline. What has emerged since is still early stage relative to the antifungal-stewardship and diagnostics response that dominates the practical fight against Candida auris today, and this report says so plainly rather than overstating pipeline maturity.
-
NovaDigm TherapeuticsPhase II completed, no Phase III to dateNDV-3A Recombinant Als3-based, alum-adjuvanted
Originally developed at the Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-UCLA and subsequently advanced by NovaDigm Therapeutics, NDV-3A remains the most clinically advanced Candida-relevant vaccine candidate. A Phase 1b/2a trial showed a single dose was safe, immunogenic and protected women under 40 from RVVC recurrence for up to 12 months; it has also been tested against Staphylococcus aureus colonization in a separate Phase 2 study. No Phase III trial has been reported to date. Preclinical work has also shown NDV-3A protects mice against multidrug-resistant C. auris infection, an early but genuine signal of cross-protective potential. -
Academic dual-antigen programmePreclinical, 2025/26 dataVXV-01 Als3p + Hyr1p dual antigen, CAF01 adjuvant
A next-generation candidate combining recombinant Als3p and Hyr1p antigens, published in 2025/26 preclinical work. VXV-01 demonstrated durable, CD4 T cell-dependent protection against C. albicans and, notably, cross-protection against multidrug-resistant C. auris in mouse models, currently the most direct C. auris-relevant vaccine signal in the literature, though still well short of clinical testing. -
Legacy academic programmesHistoric, not progressed to marketSap2-targeted candidates (e.g. recombinant Sap2/PEV7)
Earlier academic research explored recombinant secreted aspartyl proteinase 2 (Sap2) as a vaccine antigen against VVC, with some early-stage clinical testing. None of these Sap2-targeted programmes has progressed to a marketed product, and this line of research has been largely superseded by Als3/Hyr1-based approaches in the current literature. -
C. auris-specific vaccine programmesNo candidate yet in clinical trialsState of play: very early
No vaccine candidate developed specifically and solely against C. auris has yet entered clinical trials. The practical response to its spread remains concentrated in enhanced diagnostics, infection prevention and control, and antifungal stewardship, alongside next-generation antifungal drug development (for example fosmanogepix, ibrexafungerp and rezafungin), rather than in vaccination. The cross-protective preclinical data from Als3/Hyr1-based candidates represent the most advanced vaccine-relevant work bearing on C. auris to date, but this remains a genuinely early field. -
CDC & ECDC surveillance networksActive surveillanceNational and multinational C. auris surveillance
US and European surveillance networks now track C. auris case counts, healthcare-facility outbreak patterns and clade-level antifungal resistance on an ongoing basis, the evidence base this report's own epidemiology module draws upon.
No vaccine candidate aimed specifically at Candida auris has yet reached clinical trials, and NDV-3A, the most advanced Candida-relevant vaccine, has not progressed beyond Phase II. That is a genuinely early pipeline set against a fast-moving, multidrug-resistant threat that the WHO now rates critical priority. It is a marked contrast with the far more active RVVC clinical evidence base, where NDV-3A's 12-month protection data offers a real, if still unproven-at-scale, proof of concept. This report's model does not assume near-term product launch; instead it quantifies commercial opportunity across RVVC, invasive candidiasis and the emerging C. auris-relevant literature under distinct pipeline-progression scenarios.
Six analytical layers - one commercial picture
A genuinely comprehensive report spanning RVVC, invasive candidiasis and the newly distinct Candida auris threat, with scenario-based revenue forecasting across major Western markets to 2035.
Value ($m) and volume (mio doses) demand modelling to 2035 under LO/MID/HI RVVC prevalence scenarios.
A dedicated ICU-setting demand scenario for invasive candidiasis, reflecting current candidemia mortality and cost data.
Full review of NDV-3A, VXV-01 and other Als3/Hyr1/Sap2-targeted candidates, and the honest current state of C. auris-specific vaccine research.
Volume and value forecasts to 2035, modelled separately across the RVVC and invasive candidiasis indications.
WHO critical-priority classification, CDC/ECDC surveillance trends and antifungal-resistance data tracked as distinct context.
Designed as an ideal tool to aid early-stage decision making in Candida vaccine positioning, investment and market entry planning.
A glimpse of the commercial model
The table below shows a partial view of the segment, geography and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Segment | Geography | Scenario | Status | Revenue scenario |
|---|---|---|---|---|
| RVVC (LO prevalence scenario) | United States | LO | No licensed vaccine | Modelled |
| RVVC (MID prevalence scenario) | Western Europe | MID | No licensed vaccine | Modelled |
| Invasive candidiasis (ICU setting) | United States | Base | No licensed vaccine | Modelled |
| ██████████ | █████ | HI | ██████ | $██m (upside) |
| ██████████ | █████ | Base | ██████ | $██m (base) |
| Total addressable - base | All geographies | All scenarios | All indications | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and an interactive forecast model, built for organisations assessing the Candida vaccine opportunity across both its established and newly-distinct threats.
- Executive presentation - mycology and disease background, RVVC and invasive candidiasis epidemiology, a dedicated Candida auris review, and full competitive environment review
- RVVC MS-Excel demand model - value ($m)/volume (mio doses) outputs to 2035 across LO/MID/HI prevalence scenarios
- Invasive candidiasis (ICU) MS-Excel demand model - value/volume forecasts under a dedicated ICU-setting scenario, reflecting current candidemia mortality and cost data
- Western-market coverage - major Western markets modelled individually and in aggregate
- Competitor intelligence - NDV-3A, VXV-01 and other Als3/Hyr1/Sap2-targeted candidates, plus the current, honestly-assessed state of C. auris-specific vaccine research
- Candida auris epidemiology module - WHO critical-priority classification, CDC/ECDC surveillance trends and antifungal-resistance data
- Early decision-making support - positioning and market entry guidance for an early-stage but fast-moving field
Built for organisations evaluating the Candida vaccine opportunity
Most valuable to teams assessing the Candida vaccine market, including the distinct Candida auris threat, against their own pipeline, BD ambitions, investment thesis or infection-control priorities.
Vaccine developers
Positioning and commercial feasibility assessment for RVVC, invasive candidiasis and C. auris-relevant vaccine candidates.
Corporate strategy & BD
Validate market structure and commercial opportunity across a genus that spans a common mucosal condition and a critical-priority hospital pathogen.
Investors & analysts
Independent, honest assessment of a genuinely early-stage pipeline against a fast-moving, high-priority unmet need.
Hospital infection-control & antifungal stewardship teams
Context on the Candida auris surveillance, resistance and outbreak-pattern data underpinning stewardship and infection-prevention planning.
Public health & immunisation programmes
Demand modelling to support future RVVC and invasive candidiasis prevention programme planning.
Researchers & academia
Comprehensive epidemiology and pipeline landscape for grant planning and Candida/C. auris vaccine research prioritisation.
VacZine Analytics has drawn on its long standing expertise in Adolescent/STD diseases since our earliest editions, positioning us well to track a market that spans a common women's health condition, a hospital-acquired bloodstream infection and, now, a distinct multidrug-resistant threat in Candida auris. This is a very comprehensive report with wide geographic focus, well received by clients in the field for the depth of its RVVC and invasive candidiasis segmentation. Few groups have followed the Candida vaccine landscape as closely, and that recognised, independent expertise underpins everything in the analysis.
This report was last published as the 2020 edition; any refresh would incorporate current RVVC and invasive candidiasis epidemiology, the emergence of Candida auris as a WHO critical-priority pathogen, and the current state of NDV-3A, VXV-01 and other early-stage Candida vaccine candidates. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Candida vaccine analysis, including a dedicated Candida auris focus, a briefing call is included on request.